Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis (EM)-associated pain: Phase 2 safety and efficacy 24-week results

Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, Kentarou Kudou, Naoki Terakawa
In: Endocrine Abstracts · 2017 · doi:10.1530/endoabs.49.gp134 · W2618728314
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

This Phase 2 study evaluated the safety and efficacy of relugolix, an oral GnRH receptor antagonist, in women with endometriosis-associated pain, reporting 24-week results.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK